Health Care · Pharmaceutical Preparations

IDYA IDEAYA Biosciences, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 167672587 filings
Russell 2000

IDYA at a glance

IDEAYA Biosciences, Inc. (IDYA, SEC CIK 1676725) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and Form 4 insider filings as recently as October 8, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), IDEAYA Biosciences, Inc. (IDYA) reported revenue of $218.7 million (up 3024.4% from FY2024) and a net loss of $113.7 million. Diluted EPS was -$1.28.
  • As of September 30, 2026, 27 institutional investment managers tracked by SignalX reported holding IDEAYA Biosciences, Inc. (IDYA) shares worth $1.1 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Hata Yujiro S on October 6, 2026 of 25,538 shares at $37.39 per share.
  • In the last 90 days, IDYA insiders reported 0 open-market purchases ($0) and 2 open-market sales ($985K) on Form 4, a net sale of $985K.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$218.7M
+3024.4% vs prior year
Insiders · 90 days
0 buys · 2 sells
Net −$985K
13F holders
27 funds
$1.1B · −2 vs prior quarter
Latest 8-K
Nov 3, 2026
Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core oncology precision medicine with focus on synthetic lethality and antibody-drug conjugates (ADCs) targeting molecularly defined solid tumors
  • New Phase 3 neoadjuvant trial for darovasertib in primary uveal melanoma initiated, targeting eye preservation and vision improvement
  • Servier exclusive license granted for darovasertib outside U.S., upfront payment $210M plus milestones up to $320M and royalties
  • IDE849 DLL3 TOP1 ADC Phase 1 data in 100 patients shows 48% Grade 3+ TRAEs, median PFS 6.7 months, 83.3% ORR in brain metastasis at 2.4 mg/kg dose
  • GSK terminating collaboration on Pol Theta inhibitor (IDE705) and WRN inhibitor (IDE275), programs transferring back for internal development

Risk Factors

  • Regulatory risk: Servier License Agreement contract assets increased $6.0M, indicating dependency on this agreement's terms and regulatory compliance timing
  • Macroeconomic threat: Operating cash used $71.1M in 2025 and $247.6M in 2024, showing high cash burn amid volatile financing environment
  • Operational vulnerability: $10.4M accrued liabilities for CROs, CMOs, consultants, indicating heavy reliance on external research and manufacturing partners
  • Financial risk: Net loss $113.7M in 2025 with $46.1M stock-based compensation, signaling significant operating losses and dilution risk

Management Discussion & Analysis

  • Collaboration revenue $218.7M in 2025 vs $7.0M in 2024, up 3,024% driven by Servier License Agreement
  • Net loss $113.7M in 2025 vs $274.5M in 2024; loss decreased 59%, operating expenses up 13% to $378.0M
  • Research and development expenses $314.7M (+7%), general and administrative expenses $63.3M (+61%) in 2025
  • Best performing segment: Collaboration revenue surge from Servier deal; worst: continued high R&D expenses, $98.1M on darovasertib
  • Cash, cash equivalents, marketable securities $1.05B as of Dec 31, 2025; raised net $25M from equity ATM offering in 2025
  • Outlook: Cash runway sufficient for 12+ months; expecting higher R&D expenses for clinical advancement; risk of funding shortfall if capital not raised

AI summary of the IDYA 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes to risk factors disclosed in the February 17, 2026 Annual Report
  • Carried-forward risks include potential adverse effects on business, financial condition, and future results
  • Quarterly filing provides no newly triggered regulatory, operational, competitive, or financial risk વિગતો

Management Discussion & Analysis

  • Quarterly collaboration revenue $10.2M, up 16% from $8.9M in Q2 2026
  • Q3 net loss $125.7M, operating loss $137.6M, no product revenue
  • Darovasertib highest Q3 clinical spend $35.1M, IDE161 lowest at $1.4M
  • Cash, equivalents and marketable securities approximately $1.15B; operating cash used $256.9M
  • Financing cash $364.1M, including $323.4M net follow-on offering proceeds; funding expected for at least twelve months

AI summary of the IDYA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 3, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for the quarter ended September 30, 2026 announced
  • Full earnings release furnished as Exhibit 99.1, containing the detailed results and management update

Item EX-99.1: Item EX-99.1

  • Q3 2026 NDA submitted for darovasertib plus crizotinib in metastatic uveal melanoma, creating a potential near-term regulatory catalyst
  • OptimUM-010 Phase 3 enrollment stopped, with estimated cost savings of $100-125 million redirected toward IDE849 and IDE892
Filed Aug 4, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • OptimUM-02 met its primary endpoint: median PFS 6.9 months versus 3.1 months, HR 0.42, p<0.0001
  • NDA filing for darovasertib combination underway through FDA’s RTOR program, with completion expected in H2 2026

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Full results and management commentary available in Exhibit 99.1
Filed Jun 23, 2026Full analysis →

Item 8.01: Other Events

  • Yujiro S. Hata elected Board Chairman effective June 16, 2026
  • Terry Rosen, Ph.D. appointed Lead Independent Director

Item 5.07: Submission of Matters to a Vote of Security Holders

  • All three Class I director nominees elected; terms run through 2029
  • Director support varied, with Hampton receiving 56.7M votes for versus 16.3M withheld

AI summaries of IDYA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for IDYA

Don't miss the next IDYA filing

  • Alerts as it files. A push when IDYA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut IDYA, by share count.
  • Ask anything. An AI agent that reads every IDYA filing and answers with sources.

IDYA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Hata Yujiro SSellOct 6, 2026$37.39
Hata Yujiro SMOct 6, 2026$4.31
Hata Yujiro SSellOct 6, 2026$38.26
Hata Yujiro SMOct 6, 2026-
Ruiz Briseno AndresMJul 7, 2026$12.86
Ruiz Briseno AndresSellJul 7, 2026$40.01
Ruiz Briseno AndresMJul 7, 2026-
Stein JeffreyAJun 16, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$7.0M$218.7M
Operating Income-$134.4M-$327.0M-$159.3M
Net Income-$113.0M-$274.5M-$113.7M
Op. Margin--4671.1%-72.8%
Net Margin--3921.1%-52.0%
Balance Sheet
Total Assets$649.3M$1.1B$1.1B
Equity-$1.1B$1.0B
ROE--25.9%-11.1%
Per Share
EPS$-1.96$-3.36$-1.28
Cash Flow
Operating CF--$247.6M-$71.1M
CapEx-$3.9M$2.4M

Source: XBRL data in IDEAYA Biosciences, Inc. (IDYA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate IDYA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
IDYA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202627$1.13B
Q2 202629$1.61B
Q1 202628$1.34B
Q4 202524$1.39B
Q3 202526$1.04B
Q2 202526$841.6M
Q1 202522$502.5M
Q4 202420$675.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 202 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

IDYA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 3, 2026Analysis-
10-QNov 3, 2026Analysis
4Oct 8, 2026--
SC 13GAug 14, 2026-
10-QAug 4, 2026Analysis
8-KAug 4, 2026Analysis-
SC 13GJul 31, 2026-
4Jul 9, 2026--
8-KJun 23, 2026Analysis-
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
4Jun 18, 2026--
8-KJun 10, 2026Analysis
8-KJun 3, 2026Analysis
8-KJun 1, 2026Analysis
8-KMay 5, 2026Analysis-
8-KMay 5, 2026Analysis-
10-QMay 5, 2026Analysis
8-KApr 13, 2026Analysis-
8-KApr 9, 2026Analysis-
10-KFeb 17, 2026Analysis
8-KFeb 17, 2026-

Related Health Care companies

All Health Care →

IDYA SEC filings: frequently asked questions

Are IDYA insiders buying or selling?

In the last 90 days, IDEAYA Biosciences, Inc. (IDYA) officers, directors and 10% owners reported no open-market purchases and 2 open-market sales worth $985,397 by 1 insider on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold IDYA stock?

As of September 30, 2026, the largest IDEAYA Biosciences, Inc. (IDYA) holders among the 13F filers tracked by SignalX were BlackRock ($366.9 million), Vanguard Capital Management LLC ($165.7 million), State Street Corp ($150.9 million), T. Rowe Price Group ($82.0 million), Morgan Stanley ($73.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was IDYA's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), IDEAYA Biosciences, Inc. (IDYA) reported revenue of $218.7 million (up 3024.4% from FY2024) and a net loss of $113.7 million. Diluted EPS was -$1.28. The figures come from the XBRL data in the 10-K.

What are the main risks in IDYA's latest 10-K?

In the 10-K filed February 17, 2026, IDEAYA Biosciences, Inc. (IDYA) flagged: Regulatory risk: Servier License Agreement contract assets increased $6.0M, indicating dependency on this agreement's terms and regulatory compliance timing. Macroeconomic threat: Operating cash used $71.1M in 2025 and $247.6M in 2024, showing high cash burn amid volatile financing environment. (AI summary of the Risk Factors section.)

What did IDYA report in its latest 8-K?

IDEAYA Biosciences, Inc. (IDYA) filed an 8-K on November 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results for the quarter ended September 30, 2026 announced.

What are the latest IDYA SEC filings?

IDEAYA Biosciences, Inc. (IDYA) filed its latest 10-K annual report on February 17, 2026, a 10-Q quarterly report on November 3, 2026, an 8-K current report on November 3, 2026 and a Form 4 insider filing on October 8, 2026.

What is IDYA's SEC CIK number?

IDEAYA Biosciences, Inc. (IDYA)'s SEC Central Index Key (CIK) is 1676725. EDGAR lists every IDYA filing under that number.

Ask anything about IDYA

The research agent reads IDYA's filings, financials, insider trades and 13F holders, then answers with sources.